Drug Trial Radar · NCT03641560
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Sep 19, 2018
Primary completion
Feb 20, 2024
Study completion Feb 20, 2024
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Aug 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the safety and tolerability of enzalutamide in Indian patients with progressive mCRPC previously treated with docetaxel-based chemotherapy. This study also evaluated the effect of enzalutamide on prostate-specific antigen (PSA).
Conditions
- Metastatic Castration Resistant Prostate Cancer
Interventions
EnzalutamideDrug
Enzalutamide was administered orally
Androgen deprivation therapy (ADT)Drug
All participants were required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment- Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug until 30 days after last dose (Up to 1899 days)
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Site IN00002
Ahmedabad, India
Site IN00004
Hubli, India
Site IN00008
Kolkata, India
Site IN00003
Nashik, India
Site IN00007
Nashik, India
Site IN00010
New Delhi, India
Site IN00001
Pune, India
Site IN00011
Surat, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.